US 12,404,259 B2
Inhibitors of extracellular signal-regulated kinase
Adam Galan, Alameda, CA (US); Ritu Lal, Palo Alto, CA (US); Chakk Ramesha, Palo Alto, CA (US); Paul S. Shapiro, Baltimore, MD (US); Alexander D. Mackerell, Jr., Baltimore, MD (US); and Steven Fletcher, Baltimore, MD (US)
Assigned to GEN1E LIFESCIENCES INC., Palo Alto, CA (US); and UNIVERSITY OF MARYLAND, BALTIMORE, Baltimore, MD (US)
Filed by GEN1E LIFESCIENCES INC., Palo Alto, CA (US); and UNIVERSITY OF MARYLAND, BALTIMORE, Baltimore, MD (US)
Filed on Oct. 18, 2024, as Appl. No. 18/920,501.
Claims priority of provisional application 63/544,756, filed on Oct. 18, 2023.
Prior Publication US 2025/0129038 A1, Apr. 24, 2025
Int. Cl. C07D 333/48 (2006.01); A61K 31/381 (2006.01); A61P 35/00 (2006.01)
CPC C07D 333/48 (2013.01) [A61K 31/381 (2013.01); A61P 35/00 (2018.01)] 12 Claims
 
1. The compound 1,1-dioxido-2,3-dihydrothiophen-3-yl 4-phenoxybenzenesulfonate having the structure of Formula (1):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.